111 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
and diluted weighted average shares
11. Subsequent Events
On April 23, 2024, the Company entered into an exchange agreement with Fairmount Healthcare … Healthcare Fund II L.P.
8-K
Amendment No. 1 to Novation Agreement, dated April 25, 2024, by and between Paragon Therapeutics, Inc., the Company and WuXi
8-K
SYRE
Spyre Therapeutics Inc.
25 Apr 24
Unregistered Sales of Equity Securities
4:21pm
, 2024, by and between the Company and Fairmount Healthcare Fund II L.P.
Cover Page Interactive Data File (embedded within the Inline XBRL document
8-K
EX-10.1
SYRE
Spyre Therapeutics Inc.
25 Apr 24
Unregistered Sales of Equity Securities
4:21pm
.
[Signature Page Follows]
Please sign to acknowledge agreement with the above terms and return to the undersigned.
Stockholder:
FAIRMOUNT HEALTHCARE FUND … II L.P.
By: Fairmount Healthcare Fund II GP LLC
By: /s/ Tomas Kiselak
Name: Tomas Kiselak
Title: Managing Member
Acknowledged and agreed to:
SPYRE
POS AM
pi6xxq
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
424B3
lsvek1x 0l5ebi
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
80raw7 68lqbff
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
urnl 50j89
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
63zgaf
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
q23puxuq
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-10.1
nkwq5pl2e0e1nawu
5 Feb 24
Entry into a Material Definitive Agreement
7:36am